PharmaEssentia Company Description

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally.

Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia.

The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia.

In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology.

PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.

PharmaEssentia Corporation

Country	Taiwan
Founded	1990
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	131
CEO	Ko-Chung Lin

Contact Details

Address: No. 3, Park Street Taipei, 115 Taiwan
Phone	886 2 2655 7688
Website	pharmaessentia.com

Stock Details

Ticker Symbol	6446
Exchange	Taiwan Stock Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0006446008
SIC Code	2836

Key Executives

Name	Position
Ko-Chung Lin Ph.D.	Founder, Chief Executive Officer, Chief Strategy Officer and Director
Dr. Ching-Leou Teng Ph.D.	Chairman and Chief Pharmaceutical Officer
Chan-Kou Hwang Ph.D.	President, GM and Director
Snow Chang	Accounting Manager and Senior Manager of Finance
Samuel Lin	Vice President and Head of Business Operations and Strategy
Lih-Ling Lin Ph.D.	Chief Scientific Officer
Rachel Lipsitz	Vice President and Head of Corporate Communications and Advocacy
Roddy Mcilwain	Senior Vice President and Head of Sales and Marketing
Anjana Pursnani	Senior Vice President and Head of People
Dr. Albert Qin M.D., Ph.D.	Chief Medical Officer